Comparison of Buserelin to Danazol Therapy in Endometriosis

HRPI buserelin protocol 310 study group, A. Lemay
In: GnRH Analogues in Cancer and Human Reproduction · 1990 · pp. 17–31 · doi:10.1007/978-94-009-2169-6_3 · W4252201387
book-chapter OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-06 ⓘ

Endometriosis development and maintenance are influenced by ovarian steroids, with the disease typically occurring during reproductive years and regressing at menopause.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 ⓘ

This paper compares buserelin with danazol therapy for endometriosis, focusing on hormonal suppression effects as treatment for the condition, drawing on a structured buserelin protocol study group. It describes approaches in which gonadotropin-releasing hormone agonist–mediated reversible hypogonadism is evaluated against danazol’s endocrine effects, with the key finding centered on comparative efficacy within endometriosis populations treated under these regimens. The paper’s main caveat is that its evidence base reflects protocol-based therapeutic comparisons and the era’s trial designs, with outcomes influenced by endocrine variability rather than offering mechanistic confirmation of lesion etiology. This paper is centrally about endometriosis — it directly compares buserelin to danazol therapy for endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK